Published in Pediatr Cardiol on January 10, 2010
The interplay between drugs and the kidney in premature neonates. Pediatr Nephrol (2013) 0.78
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet (1982) 6.06
Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med (1976) 3.30
Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. J Pediatr (2008) 2.72
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr (1983) 2.65
Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med (1976) 2.59
Patent ductus arteriosus: evidence for and against treatment. J Pediatr (2007) 2.10
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr (2007) 2.07
Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr (1995) 1.72
Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr (2002) 1.65
Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics (2007) 1.61
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med (1981) 1.24
Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics (2008) 1.21
Unilateral vocal cord paralysis following patent ductus arteriosus ligation in extremely low-birth-weight infants. Arch Otolaryngol Head Neck Surg (2008) 1.12
Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. J Pediatr Surg (1993) 1.10
Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. J Pediatr (1984) 1.01
Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med (2002) 0.95
Optimum Use of Therapeutic Drug Monitoring and Pharmacokinetics-Pharmacodynamics in the NICU. J Pediatr Pharmacol Ther (2009) 0.94
The disposition of indomethacin in preterm babies. J Pediatr (1980) 0.91
Indomethacin therapy for large patent ductus arteriosus in the very low birth weight infant: results and complications. Pediatrics (1979) 0.90
Treatment to prevent patency of the ductus arteriosus: beneficial or harmful? J Pediatr (2006) 0.89
Closure of the patent ductus arteriosus with ligation and indomethacin: a consecutive experience. J Pediatr (1978) 0.88
Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus. J Pediatr (1982) 0.86
Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus--clinical and echocardiographic assessments of response. J Pediatr (1979) 0.86
Vocal fold paralysis following surgical ductal closure in extremely low birth weight infants: a case series of feeding and respiratory complications. J Perinatol (2008) 0.86
Induction of surfactant protein A expression by cortisol facilitates prostaglandin synthesis in human chorionic trophoblasts. J Clin Endocrinol Metab (2006) 0.83
Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure. Ther Drug Monit (1991) 0.80
Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response. J Perinatol (1990) 0.79
Reopening of the ductus arteriosus after closure with indomethacin: importance of sustained effective indomethacin serum concentrations. J Pediatr (1996) 0.79
High-performance liquid chromatographic determination of indomethacin serum concentrations. J Chromatogr (1988) 0.76
Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all? J Pediatr Pharmacol Ther (2009) 0.75
Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology (2009) 1.10
Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis (2010) 1.10
Efficacy of sucrose to reduce pain in premature infants during eye examinations for retinopathy of prematurity. Ann Pharmacother (2005) 1.09
A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci U S A (2009) 1.04
Efficacy of topical anesthetics to reduce pain in premature infants during eye examinations for retinopathy of prematurity. Ann Pharmacother (2005) 1.00
Heat loss prevention for preterm infants in the delivery room. J Perinatol (2005) 0.97
Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med (2002) 0.95
Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. J Pediatr Pharmacol Ther (2012) 0.93
Treatment of Citrobacter koseri infection with ciprofloxacin and cefotaxime in a preterm infant. Ann Pharmacother (2008) 0.88
Low-dose aminophylline for the treatment of neonatal non-oliguric renal failure-case series and review of the literature. J Pediatr Pharmacol Ther (2008) 0.88
Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair. Cells Tissues Organs (2011) 0.88
Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight < 1000 grams: a sequential analysis. BMC Pediatr (2012) 0.85
Successful use of dexmedetomidine for sedation in a 24-week gestational age neonate. Ann Pharmacother (2009) 0.82
Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. Ann Pharmacother (2010) 0.82
Cyclic chalcone analogue KRP6 as a potent modulator of cell proliferation: an in vitro study in HUVECs. Mol Biol Rep (2013) 0.78
Treatment of seizures in newborns: the dilemma of starting the right drug, at the right time, in the right doses, and monitoring the right endpoints. J Pediatr Pharmacol Ther (2005) 0.77
Possible Ibuprofen-induced kernicterus in a near-term infant with moderate hyperbilirubinemia. J Pediatr Pharmacol Ther (2006) 0.77
Lepirudin use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother (2003) 0.77
Aminophylline compatibility with neonatal total parenteral nutrition. J Pediatr Pharmacol Ther (2008) 0.76
History of neonatal medicine-limitations in studies, guidelines, and resources impact progress. J Pediatr Pharmacol Ther (2005) 0.75
Infasurf and curosurf: theoretical and practical considerations with new surfactants. J Pediatr Pharmacol Ther (2003) 0.75
Postnatal Steroids to Treat Chronic Lung Disease in Preterm Infants: Is it Ever Justified? J Pediatr Pharmacol Ther (2005) 0.75